MIM
ODT

Monashee Investment Management’s Odonate Therapeutics, Inc. Common Stock ODT Stock Holding History

Monashee Investment Management’s Portfolio ODT Stock Details ODT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-20,000
Closed -$734K – 202
2019
Q2 		$734K Buy
+20,000
New +$479K 0.19% 97
2017
Q4 		– Hold
0
– – – 25

Other funds holding ODT

TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return

Monashee Investment Management's ODT Position: Q3 2019 in Review

Monashee Investment Management sold out of Odonate Therapeutics, Inc. Common Stock (ODT) in Q3 2019, closing a stake of 20,000 shares — an estimated $734K sold.

Monashee Investment Management first reported a position in ODT in Q2 2019 and held it in 1 quarter. The position peaked at $734K in Q2 2019. 82 funds tracked by Wall St. Rank hold ODT as of Q3 2019.

  • Monashee Investment Management reported no remaining Odonate Therapeutics, Inc. Common Stock position as of Q3 2019 after selling out during the quarter.
  • Monashee Investment Management sold 20,000 Odonate Therapeutics, Inc. Common Stock shares in Q3 2019, an estimated $734K.
  • Monashee Investment Management first reported a position in Odonate Therapeutics, Inc. Common Stock in Q2 2019 and held it in 1 quarter.
  • Monashee Investment Management's Odonate Therapeutics, Inc. Common Stock position peaked at $734K in Q2 2019.
  • 82 funds tracked by Wall St. Rank held Odonate Therapeutics, Inc. Common Stock as of Q3 2019.

Based on Monashee Investment Management's 13F filing for Q3 2019, filed 12 Nov 2019.